- Endo's Fortesta receives FDA approval
- Mylan sponsors Drug Store News and Pharmacist Society to provide a new business networking platform for pharmacy schools and students
- Endo addresses possible short-term supply of Opana ER, other drugs
- Endo launches Fortesta
- GPhA announces executive committee, board of directors
PITTSBURGH — A generic drug maker has launched its version of a pain medication made by Endo Pharmaceuticals.
Mylan and its subsidiary Mylan Pharmaceuticals launched oxycodone and aspirin tablets USP in the 4.8355-mg/325-mg strength, based on an agreement with licensing partner Coastal Pharmaceuticals. The drug, designed to treat moderate to severe pain, is a generic version of Percodan.
Oxycodone and aspirin tablets had U.S. sales of approximately $6.5 million for the 12 months ended Dec. 31, 2010, according to IMS Health.
Currently, Mylan has 169 ANDAs pending approval from the Food and Drug Administration, the company said.